Vol. 1 No. 9 (2021)
Reimbursement Recommendations

Budesonide-Glycopyrronium-Formoterol Fumarate Dihydrate (Breztri Aerosphere)

  • Reimbursement Team
PDF HTML
DOI: https://doi.org/10.51731/cjht.2021.148

Published September 14, 2021

Key Messages

  • CADTH recommends that Breztri Aerosphere be reimbursed by public drug plans for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema if certain conditions are met.

  • Breztri Aerosphere should only be covered to treat patients who are not controlled on optimal dual inhaled therapy for COPD.

  • Breztri Aerosphere should be reimbursed similar to Trelegy Ellipta. The price of Breztri Aerosphere should not exceed the drug program cost with the least-costly fixed-dose inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta2-agonist (ICS/LAMA/LABA) triple therapy combination for the same indication.

PDF HTML